Abiraterone
The therapeutic efficacy of Abiraterone can be decreased when used in combination with Spironolactone.
Acebutolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Acebutolol.
Aceclofenac
Aceclofenac may decrease the antihypertensive activities of Spironolactone.
Advertisement
Acemetacin
The therapeutic efficacy of Spironolactone can be decreased when used in combination with Acemetacin.
Acetyl salicylate
Acetylsalicylic acid may decrease the antihypertensive activities of Spironolactone.
Acetyldigitoxin
The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Spironolactone.
Advertisement
Adapalene
Adapalene may decrease the antihypertensive activities of Spironolactone.
Adrafinil
Spironolactone may decrease the vasoconstricting activities of Adrafinil.
Afatinib
The serum concentration of Afatinib can be increased when it is combined with Spironolactone.
Advertisement
Albuterol
Spironolactone may decrease the vasoconstricting activities of Salbutamol.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Spironolactone.
Alfentanil
The risk or severity of adverse effects can be increased when Alfentanil is combined with Spironolactone.
Aliskiren
The risk or severity of adverse effects can be increased when Spironolactone is combined with Aliskiren.
Alminoprofen
Alminoprofen may decrease the antihypertensive activities of Spironolactone.
Alphaprodine
The risk or severity of adverse effects can be increased when Alphaprodine is combined with Spironolactone.
Amifostine
The risk or severity of adverse effects can be increased when Amifostine is combined with Spironolactone.
Amifostine Anhydrous
The risk or severity of adverse effects can be increased when Amifostine is combined with Spironolactone.
Amiloride
Amiloride may increase the hyperkalemic activities of Spironolactone.
Amiodarone
The risk or severity of adverse effects can be increased when Amiodarone is combined with Spironolactone.
Amlodipine
The risk or severity of adverse effects can be increased when Amlodipine is combined with Spironolactone.
Ammonium Chloride
The risk or severity of adverse effects can be increased when Spironolactone is combined with Ammonium chloride.
Amobarbital
Amobarbital may increase the hypotensive activities of Spironolactone.
Amodiaquine
The serum concentration of Amodiaquine can be increased when it is combined with Spironolactone.
Amphotericin B
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Spironolactone.
amphotericin B liposomal
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Spironolactone.
Amyl Nitrite
The risk or severity of adverse effects can be increased when Spironolactone is combined with Amyl Nitrite.
Anhydrous Tacrolimus
The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus.
Antipyrine
Antipyrine may decrease the antihypertensive activities of Spironolactone.
Apazone
Azapropazone may decrease the antihypertensive activities of Spironolactone.
Apomorphine
The risk or severity of adverse effects can be increased when Apomorphine is combined with Spironolactone.
Apraclonidine
Spironolactone may decrease the vasoconstricting activities of Apraclonidine.
Apremilast
Apremilast may decrease the antihypertensive activities of Spironolactone.
Arbutamine
Spironolactone may decrease the vasoconstricting activities of Arbutamine.
Ardeparin
Ardeparin may increase the hyperkalemic activities of Spironolactone.
Arformoterol
Spironolactone may decrease the vasoconstricting activities of Arformoterol.
Aripiprazole
Aripiprazole may increase the hypotensive activities of Spironolactone.
Arsenic Trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Spironolactone.
Aspirin
Acetylsalicylic acid may decrease the antihypertensive activities of Spironolactone.
Atenolol
The risk or severity of adverse effects can be increased when Atenolol is combined with Spironolactone.
Atracurium Besylate
Spironolactone may increase the neuromuscular blocking activities of Atracurium besylate.
Azelastine
Azelastine may decrease the antihypertensive activities of Spironolactone.
Azilsartan
The risk or severity of adverse effects can be increased when Spironolactone is combined with Azilsartan medoxomil.
Azilsartan kamedoxomil
The risk or severity of adverse effects can be increased when Spironolactone is combined with Azilsartan medoxomil.
Azilsartan Medoxomil
The risk or severity of adverse effects can be increased when Spironolactone is combined with Azilsartan medoxomil.
Balsalazide
Balsalazide may decrease the antihypertensive activities of Spironolactone.
Barbexaclone
Barbexaclone may increase the hypotensive activities of Spironolactone.
Barbital
Barbital may increase the hypotensive activities of Spironolactone.
Bemiparin
Bemiparin may increase the hyperkalemic activities of Spironolactone.
Benazepril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Benazepril.
Bendroflumethiazide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Bendroflumethiazide.
Benzydamine
Benzydamine may decrease the antihypertensive activities of Spironolactone.
Bepridil
The risk or severity of adverse effects can be increased when Bepridil is combined with Spironolactone.
Betaxolol
The risk or severity of adverse effects can be increased when Betaxolol is combined with Spironolactone.
Bisoprolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Bisoprolol.
Bitolterol
Spironolactone may decrease the vasoconstricting activities of Bitolterol.
Bitolterol Mesylate
Spironolactone may decrease the vasoconstricting activities of Bitolterol.
Bortezomib
The risk or severity of adverse effects can be increased when Bortezomib is combined with Spironolactone.
Bosutinib
The serum concentration of Bosutinib can be increased when it is combined with Spironolactone.
Bosutinib monohydrate
The serum concentration of Bosutinib can be increased when it is combined with Spironolactone.
Brentuximab Vedotin
The serum concentration of Brentuximab vedotin can be increased when it is combined with Spironolactone.
Bretylium
The risk or severity of adverse effects can be increased when Spironolactone is combined with Bretylium.
Brimonidine
Spironolactone may decrease the vasoconstricting activities of Brimonidine.
Bromfenac
Bromfenac may decrease the antihypertensive activities of Spironolactone.
Bromocriptine
The risk or severity of adverse effects can be increased when Bromocriptine is combined with Spironolactone.
Bufexamac
Bufexamac may decrease the antihypertensive activities of Spironolactone.
Bumetanide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Bumetanide.
Bupivacaine
The risk or severity of adverse effects can be increased when Bupivacaine is combined with Spironolactone.
Buprenorphine
The risk or severity of adverse effects can be increased when Buprenorphine is combined with Spironolactone.
Butorphanol
The risk or severity of adverse effects can be increased when Butorphanol is combined with Spironolactone.
Canagliflozin
Canagliflozin may increase the hyperkalemic activities of Spironolactone.
Canagliflozin Anhydrous
Canagliflozin may increase the hyperkalemic activities of Spironolactone.
Candesartan
Candesartan may increase the hyperkalemic activities of Spironolactone.
Candesartan Cilexetil
The risk or severity of hypotension can be increased when Candesartan cilexetil is combined with Spironolactone.
Captopril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Captopril.
Carprofen
Carprofen may decrease the antihypertensive activities of Spironolactone.
Carteolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Carteolol.
Carvedilol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Carvedilol.
Celecoxib
Celecoxib may decrease the antihypertensive activities of Spironolactone.
Certoparin
Certoparin may increase the hyperkalemic activities of Spironolactone.
Chloroquine
Chloroquine may decrease the antihypertensive activities of Spironolactone.
Chlorothiazide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Chlorothiazide.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Spironolactone.
Chlorthalidone
The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Spironolactone.
Cholestyramine Resin
The risk or severity of adverse effects can be increased when Cholestyramine is combined with Spironolactone.
Choline Magnesium Trisalicyclate
Choline magnesium trisalicylate may decrease the antihypertensive activities of Spironolactone.
Cilazapril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Cilazapril.
Ciprofloxacin
Spironolactone may increase the arrhythmogenic activities of Ciprofloxacin.
Clenbuterol
Spironolactone may decrease the vasoconstricting activities of Clenbuterol.
Clevidipine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.
Clevidipine butyrate
The risk or severity of adverse effects can be increased when Spironolactone is combined with Clevidipine.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Spironolactone.
Clomipramine
The risk or severity of adverse effects can be increased when Clomipramine is combined with Spironolactone.
Clonidine
Spironolactone may decrease the vasoconstricting activities of Clonidine.
Clonixin
Clonixin may decrease the antihypertensive activities of Spironolactone.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Spironolactone.
Codeine
The risk or severity of adverse effects can be increased when Codeine is combined with Spironolactone.
Codeine Anhydrous
The risk or severity of adverse effects can be increased when Codeine is combined with Spironolactone.
CODEINE POLISTIREX
The risk or severity of adverse effects can be increased when Codeine is combined with Spironolactone.
Colchicine
The serum concentration of Colchicine can be increased when it is combined with Spironolactone.
Conivaptan
The risk or severity of adverse effects can be increased when Conivaptan is combined with Spironolactone.
Curcumin
Curcumin may decrease the antihypertensive activities of Spironolactone.
Cyclosporine
The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Cyclosporine.
Dabigatran Etexilate
The serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Spironolactone.
Dalteparin
Dalteparin may increase the hyperkalemic activities of Spironolactone.
Dapagliflozin
The risk or severity of adverse effects can be increased when Spironolactone is combined with Dapagliflozin.
Desflurane
The risk or severity of adverse effects can be increased when Desflurane is combined with Spironolactone.
Deslanoside
The therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone.
Dexmedetomidine
Spironolactone may decrease the vasoconstricting activities of Dexmedetomidine.
Dextromoramide
The risk or severity of adverse effects can be increased when Dextromoramide is combined with Spironolactone.
Dezocine
The risk or severity of adverse effects can be increased when Dezocine is combined with Spironolactone.
Dichlorphenamide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Diclofenamide.
Diclofenac
Diclofenac may decrease the antihypertensive activities of Spironolactone.
Diflunisal
Diflunisal may decrease the antihypertensive activities of Spironolactone.
Digitoxin
The therapeutic efficacy of Digitoxin can be decreased when used in combination with Spironolactone.
Digoxin
The serum concentration of Digoxin can be increased when it is combined with Spironolactone.
Dihydrocodeine
The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Spironolactone.
Diltiazem
The risk or severity of adverse effects can be increased when Diltiazem is combined with Spironolactone.
Dinutuximab
The risk or severity of adverse effects can be increased when Spironolactone is combined with Dinutuximab.
Diphenoxylate
The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Spironolactone.
Dipivefrin
Spironolactone may decrease the vasoconstricting activities of Dipivefrin.
Dipyridamole
The risk or severity of adverse effects can be increased when Spironolactone is combined with Dipyridamole.
Dipyrone
Metamizole may decrease the antihypertensive activities of Spironolactone.
Dobutamine
Spironolactone may decrease the vasoconstricting activities of Dobutamine.
Dopexamine
Spironolactone may decrease the vasoconstricting activities of Dopexamine.
Doxazosin
The risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.
Doxorubicin
The serum concentration of Doxorubicin can be increased when it is combined with Spironolactone.
Doxorubicin Hydrochloride
The serum concentration of Doxorubicin can be increased when it is combined with Spironolactone.
Drospirenone
Drospirenone may increase the hyperkalemic activities of Spironolactone.
Droxicam
Droxicam may decrease the antihypertensive activities of Spironolactone.
Droxidopa
Spironolactone may decrease the vasoconstricting activities of Droxidopa.
Duloxetine
Spironolactone may increase the orthostatic hypotensive activities of Duloxetine.
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Spironolactone.
Empagliflozin
The risk or severity of adverse effects can be increased when Spironolactone is combined with Empagliflozin.
Enalapril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Enalapril.
Enalaprilat
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Spironolactone.
Enalaprilat Anhydrous
The risk or severity of adverse effects can be increased when Enalaprilat is combined with Spironolactone.
Enoxaparin
Enoxaparin may increase the hyperkalemic activities of Spironolactone.
Enoxaparin sodium
Enoxaparin may increase the hyperkalemic activities of Spironolactone.
Ephedrine
Spironolactone may decrease the vasoconstricting activities of Ephedrine.
Epinastine
Spironolactone may decrease the vasoconstricting activities of Epinastine.
Epinephrine
Spironolactone may decrease the vasoconstricting activities of Epinephrine.
Eplerenone
Eplerenone may increase the hyperkalemic activities of Spironolactone.
Epoprostenol
The risk or severity of adverse effects can be increased when Epoprostenol is combined with Spironolactone.
Eprosartan
The risk or severity of adverse effects can be increased when Spironolactone is combined with Eprosartan.
Ergotamine
Spironolactone may decrease the vasoconstricting activities of Ergotamine.
Esmolol
The risk or severity of adverse effects can be increased when Esmolol is combined with Spironolactone.
Etanercept
Etanercept may decrease the antihypertensive activities of Spironolactone.
Ethacrynate
The risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.
Ethacrynic Acid
The risk or severity of adverse effects can be increased when Spironolactone is combined with Etacrynic acid.
Ethylmorphine
The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Spironolactone.
Etilefrine
Spironolactone may decrease the vasoconstricting activities of Etilefrine.
Etodolac
Etodolac may decrease the antihypertensive activities of Spironolactone.
Etofenamate
Etofenamate may decrease the antihypertensive activities of Spironolactone.
Etoricoxib
Etoricoxib may decrease the antihypertensive activities of Spironolactone.
Evening primrose oil
Evening primrose oil may decrease the antihypertensive activities of Spironolactone.
Everolimus
The serum concentration of Everolimus can be increased when it is combined with Spironolactone.
Felbinac
Felbinac may decrease the antihypertensive activities of Spironolactone.
Felodipine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Felodipine.
Fenbufen
Fenbufen may decrease the antihypertensive activities of Spironolactone.
Fenoldopam
The risk or severity of adverse effects can be increased when Fenoldopam is combined with Spironolactone.
Fenoprofen
Fenoprofen may decrease the antihypertensive activities of Spironolactone.
Fenoterol
Spironolactone may decrease the vasoconstricting activities of Fenoterol.
Fentanyl
The risk or severity of adverse effects can be increased when Fentanyl is combined with Spironolactone.
Ferulic Acid
Ferulic acid may decrease the antihypertensive activities of Spironolactone.
Floctafenine
Floctafenine may decrease the antihypertensive activities of Spironolactone.
Flurbiprofen
Flurbiprofen may decrease the antihypertensive activities of Spironolactone.
Formoterol
Spironolactone may decrease the vasoconstricting activities of Formoterol.
Fosinopril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Fosinopril.
Furosemide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Furosemide.
Guanabenz
Spironolactone may decrease the vasoconstricting activities of Guanabenz.
Guanfacine
Spironolactone may decrease the vasoconstricting activities of Guanfacine.
Halothane
The risk or severity of adverse effects can be increased when Halothane is combined with Spironolactone.
Heparin
Heparin may increase the hyperkalemic activities of Spironolactone.
Heroin
The risk or severity of adverse effects can be increased when Heroin is combined with Spironolactone.
Hexobarbital
Hexobarbital may increase the hypotensive activities of Spironolactone.
Hexoprenaline
Spironolactone may decrease the vasoconstricting activities of Hexoprenaline.
Hydralazine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Hydralazine.
Hydrochlorothiazide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Hydrochlorothiazide.
Hydrocodone
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.
HYDROCODONE POLISTIREX
The risk or severity of adverse effects can be increased when Hydrocodone is combined with Spironolactone.
Hydroflumethiazide
The risk or severity of adverse effects can be increased when Hydroflumethiazide is combined with Spironolactone.
Hydromorphone
The risk or severity of adverse effects can be increased when Hydromorphone is combined with Spironolactone.
Ibuprofen
Ibuprofen may decrease the antihypertensive activities of Spironolactone.
Icatibant
Icatibant may decrease the antihypertensive activities of Spironolactone.
Iloprost
The risk or severity of adverse effects can be increased when Iloprost is combined with Spironolactone.
Imidapril
The risk or severity of adverse effects can be increased when Imidapril is combined with Spironolactone.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Spironolactone.
Indapamide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Indapamide.
Indobufen
Indobufen may decrease the antihypertensive activities of Spironolactone.
Indomethacin
Indomethacin may decrease the antihypertensive activities of Spironolactone.
Indoramin
The risk or severity of adverse effects can be increased when Indoramin is combined with Spironolactone.
Irbesartan
The risk or severity of adverse effects can be increased when Spironolactone is combined with Irbesartan.
Isocarboxazid
The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Spironolactone.
Isoetharine
Spironolactone may decrease the vasoconstricting activities of Isoetarine.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Spironolactone.
Isoproterenol
Spironolactone may decrease the vasoconstricting activities of Isoprenaline.
Isosorbide Dinitrate
The risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Dinitrate.
Isosorbide Mononitrate
The risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Mononitrate.
Isoxsuprine
Spironolactone may decrease the vasoconstricting activities of Isoxsuprine.
Isradipine
The risk or severity of adverse effects can be increased when Isradipine is combined with Spironolactone.
Kebuzone
Kebuzone may decrease the antihypertensive activities of Spironolactone.
Ketoprofen
Ketoprofen may decrease the antihypertensive activities of Spironolactone.
Ketorolac
Ketorolac may decrease the antihypertensive activities of Spironolactone.
Labetalol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Labetalol.
Lacidipine
Spironolactone may increase the hypotensive activities of Lacidipine.
Ledipasvir
The serum concentration of Ledipasvir can be increased when it is combined with Spironolactone.
Leflunomide
Leflunomide may decrease the antihypertensive activities of Spironolactone.
Lercanidipine
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Spironolactone.
Levobunolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Levobunolol.
Levobupivacaine
The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Spironolactone.
Levodopa
Spironolactone may increase the orthostatic hypotensive activities of Levodopa.
Levomethadyl
The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Spironolactone.
Levorphanol
The risk or severity of adverse effects can be increased when Levorphanol is combined with Spironolactone.
Levosimendan
The risk or severity of adverse effects can be increased when Levosimendan is combined with Spironolactone.
Limonene, (+)-
(4R)-limonene may decrease the antihypertensive activities of Spironolactone.
Lisinopril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril.
Lisinopril Anhydrous
The risk or severity of adverse effects can be increased when Spironolactone is combined with Lisinopril.
Lofexidine
Spironolactone may decrease the vasoconstricting activities of Lofexidine.
Lornoxicam
Lornoxicam may decrease the antihypertensive activities of Spironolactone.
Losartan
The risk or severity of adverse effects can be increased when Spironolactone is combined with Losartan.
Loxoprofen
Loxoprofen may decrease the antihypertensive activities of Spironolactone.
Magnesium Salicylate
Magnesium salicylate may decrease the antihypertensive activities of Spironolactone.
Mannitol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Mannitol.
Masoprocol
Masoprocol may decrease the antihypertensive activities of Spironolactone.
Mecamylamine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine.
Meclofenamate
Meclofenamic acid may decrease the antihypertensive activities of Spironolactone.
Meclofenamic Acid
Meclofenamic acid may decrease the antihypertensive activities of Spironolactone.
Mefenamic Acid
Mefenamic acid may decrease the antihypertensive activities of Spironolactone.
Meloxicam
Meloxicam may decrease the antihypertensive activities of Spironolactone.
Meperidine
The risk or severity of adverse effects can be increased when Pethidine is combined with Spironolactone.
Mephentermine
Spironolactone may decrease the vasoconstricting activities of Mephentermine.
Mephobarbital
Methylphenobarbital may increase the hypotensive activities of Spironolactone.
Mepirodipine
The risk or severity of adverse effects can be increased when Barnidipine is combined with Spironolactone.
Mesalamine
Mesalazine may decrease the antihypertensive activities of Spironolactone.
Metaproterenol
Spironolactone may decrease the vasoconstricting activities of Orciprenaline.
Metaraminol
Spironolactone may decrease the vasoconstricting activities of Metaraminol.
Methadone
The risk or severity of adverse effects can be increased when Methadone is combined with Spironolactone.
Methadyl Acetate
The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Spironolactone.
Methazolamide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Methazolamide.
Methohexital
Methohexital may increase the hypotensive activities of Spironolactone.
Methoxamine
Spironolactone may decrease the vasoconstricting activities of Methoxamine.
Methyclothiazide
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone.
Methyldopa
Spironolactone may decrease the vasoconstricting activities of Methyldopa.
METHYLDOPA ANHYDROUS
Spironolactone may decrease the vasoconstricting activities of Methyldopa.
Metipranolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Metipranolol.
Metolazone
The risk or severity of adverse effects can be increased when Spironolactone is combined with Metolazone.
Metoprolol
The risk or severity of adverse effects can be increased when Metoprolol is combined with Spironolactone.
Midodrine
Spironolactone may decrease the vasoconstricting activities of Midodrine.
Minoxidil
The risk or severity of adverse effects can be increased when Minoxidil is combined with Spironolactone.
Mirabegron
Spironolactone may decrease the vasoconstricting activities of Mirabegron.
Mitotane
The therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone.
Mivacurium
Spironolactone may increase the neuromuscular blocking activities of Mivacurium.
Moexipril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Moexipril.
Morphine
The risk or severity of adverse effects can be increased when Morphine is combined with Spironolactone.
Moxonidine
The risk or severity of adverse effects can be increased when Moxonidine is combined with Spironolactone.
MYCOPHENOLATE
Mycophenolic acid may decrease the antihypertensive activities of Spironolactone.
Mycophenolate Mofetil
Mycophenolate mofetil may decrease the antihypertensive activities of Spironolactone.
Mycophenolic Acid
Mycophenolic acid may decrease the antihypertensive activities of Spironolactone.
Nabilone
The risk or severity of adverse effects can be increased when Nabilone is combined with Spironolactone.
Nabumetone
Nabumetone may decrease the antihypertensive activities of Spironolactone.
Nadolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Nadolol.
Nadroparin
Nadroparin may increase the hyperkalemic activities of Spironolactone.
Naftifine
Naftifine may decrease the antihypertensive activities of Spironolactone.
Nalbuphine
The risk or severity of adverse effects can be increased when Nalbuphine is combined with Spironolactone.
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Spironolactone.
Naphazoline
Spironolactone may decrease the vasoconstricting activities of Naphazoline.
Naproxen
Naproxen may decrease the antihypertensive activities of Spironolactone.
Nebivolol
Spironolactone may decrease the vasoconstricting activities of Nebivolol.
Nepafenac
Nepafenac may decrease the antihypertensive activities of Spironolactone.
Nesiritide
The risk or severity of adverse effects can be increased when Spironolactone is combined with Nesiritide.
Nicardipine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Nicardipine.
Nicorandil
Nicorandil may increase the hypotensive activities of Spironolactone.
Nifedipine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Nifedipine.
Niflumic Acid
Niflumic Acid may decrease the antihypertensive activities of Spironolactone.
Nilvadipine
The risk or severity of adverse effects can be increased when Nilvadipine is combined with Spironolactone.
Nimesulide
Nimesulide may decrease the antihypertensive activities of Spironolactone.
Nimodipine
The risk or severity of adverse effects can be increased when Nimodipine is combined with Spironolactone.
Nisoldipine
The risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone.
Nitrendipine
The risk or severity of adverse effects can be increased when Nitrendipine is combined with Spironolactone.
Nitric Oxide
The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Spironolactone.
Nitrofurantoin
Nitrofurantoin may increase the hyperkalemic activities of Spironolactone.
NITROFURANTOIN, MACROCRYSTALS
Nitrofurantoin may increase the hyperkalemic activities of Spironolactone.
Nitroglycerin
The risk or severity of adverse effects can be increased when Spironolactone is combined with Nitroglycerin.
Nitroprusside
The risk or severity of adverse effects can be increased when Nitroprusside is combined with Spironolactone.
Norepinephrine
Spironolactone may decrease the vasoconstricting activities of Norepinephrine.
Normethadone
The risk or severity of adverse effects can be increased when Normethadone is combined with Spironolactone.
Nylidrin
Spironolactone may decrease the vasoconstricting activities of Nylidrin.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Spironolactone.
Oenothera biennis seed extract
Evening primrose oil may decrease the antihypertensive activities of Spironolactone.
Olmesartan
The risk or severity of adverse effects can be increased when Olmesartan is combined with Spironolactone.
Olodaterol
Spironolactone may decrease the vasoconstricting activities of Olodaterol.
Olopatadine
Olopatadine may decrease the antihypertensive activities of Spironolactone.
Olsalazine
Olsalazine may decrease the antihypertensive activities of Spironolactone.
Opium
The risk or severity of adverse effects can be increased when Opium is combined with Spironolactone.
Ouabain
The therapeutic efficacy of Ouabain can be decreased when used in combination with Spironolactone.
Ovine Digoxin Immune Fab
The therapeutic efficacy of Digoxin Immune Fab (Ovine) can be decreased when used in combination with Spironolactone.
Oxaprozin
Oxaprozin may decrease the antihypertensive activities of Spironolactone.
Oxprenolol
The risk or severity of adverse effects can be increased when Oxprenolol is combined with Spironolactone.
Oxycodone
The risk or severity of adverse effects can be increased when Oxycodone is combined with Spironolactone.
Oxymetazoline
Spironolactone may decrease the vasoconstricting activities of Oxymetazoline.
Oxymorphone
The risk or severity of adverse effects can be increased when Oxymorphone is combined with Spironolactone.
Oxyphenbutazone
Oxyphenbutazone may decrease the antihypertensive activities of Spironolactone.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Spironolactone.
Papaverine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Papaverine.
Parecoxib
Parecoxib may decrease the antihypertensive activities of Spironolactone.
Paregoric
The risk or severity of adverse effects can be increased when Morphine is combined with Spironolactone.
Parnaparin
Parnaparin may increase the hyperkalemic activities of Spironolactone.
Parthenolide
Parthenolide may decrease the antihypertensive activities of Spironolactone.
Pazopanib
The serum concentration of Pazopanib can be increased when it is combined with Spironolactone.
Penbutolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Penbutolol.
Pentazocine
The risk or severity of adverse effects can be increased when Pentazocine is combined with Spironolactone.
Pentobarbital
Pentobarbital may increase the hypotensive activities of Spironolactone.
Perindopril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Perindopril.
Phenelzine
The risk or severity of adverse effects can be increased when Phenelzine is combined with Spironolactone.
Phenobarbital
Phenobarbital may increase the hypotensive activities of Spironolactone.
Phenoxybenzamine
The risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Spironolactone.
Phentolamine
The risk or severity of adverse effects can be increased when Phentolamine is combined with Spironolactone.
Phentolamine Mesylate
The risk or severity of adverse effects can be increased when Phentolamine is combined with Spironolactone.
Phenylbutazone
Phenylbutazone may decrease the antihypertensive activities of Spironolactone.
Phenylephrine
Spironolactone may decrease the vasoconstricting activities of Phenylephrine.
Phenylpropanolamine
Spironolactone may decrease the vasoconstricting activities of Phenylpropanolamine.
Pimecrolimus
Pimecrolimus may decrease the antihypertensive activities of Spironolactone.
Pindolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Pindolol.
Pipamperone
The risk or severity of adverse effects can be increased when Pipamperone is combined with Spironolactone.
Pirbuterol
Spironolactone may decrease the vasoconstricting activities of Pirbuterol.
Pirfenidone
Pirfenidone may decrease the antihypertensive activities of Spironolactone.
Pirinitramide
The risk or severity of adverse effects can be increased when Piritramide is combined with Spironolactone.
Piroxicam
Piroxicam may decrease the antihypertensive activities of Spironolactone.
Piroxicam-Beta-Cyclodextrin
Piroxicam may decrease the antihypertensive activities of Spironolactone.
Pramipexole
The risk or severity of adverse effects can be increased when Pramipexole is combined with Spironolactone.
Prazosin
The risk or severity of adverse effects can be increased when Spironolactone is combined with Prazosin.
Primidone
Primidone may increase the hypotensive activities of Spironolactone.
Procaterol
Spironolactone may decrease the vasoconstricting activities of Procaterol.
Propofol
The risk or severity of adverse effects can be increased when Propofol is combined with Spironolactone.
Propoxyphene
The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Spironolactone.
Propranolol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Propranolol.
Proscillaridin
The therapeutic efficacy of Proscillaridin can be decreased when used in combination with Spironolactone.
Pseudoephedrine
Spironolactone may decrease the vasoconstricting activities of Pseudoephedrine.
Quetiapine
The risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.
Quetiapine fumarate
The risk or severity of adverse effects can be increased when Spironolactone is combined with Quetiapine.
Quinapril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Quinapril.
Quinidine
The therapeutic efficacy of Quinidine can be decreased when used in combination with Spironolactone.
Racepinephrine
Spironolactone may decrease the vasoconstricting activities of Racepinephrine.
Ramipril
The risk or severity of adverse effects can be increased when Ramipril is combined with Spironolactone.
Ranolazine
The serum concentration of Ranolazine can be increased when it is combined with Spironolactone.
Rapacuronium
Spironolactone may increase the neuromuscular blocking activities of Rapacuronium.
Rasagiline
The risk or severity of adverse effects can be increased when Rasagiline is combined with Spironolactone.
Remifentanil
The risk or severity of adverse effects can be increased when Remifentanil is combined with Spironolactone.
Reproterol
Spironolactone may decrease the vasoconstricting activities of Reproterol.
Rescinnamine
Spironolactone may increase the hyperkalemic activities of Rescinnamine.
Reserpine
The risk or severity of adverse effects can be increased when Reserpine is combined with Spironolactone.
Resveratrol
Resveratrol may decrease the antihypertensive activities of Spironolactone.
Reviparin
Reviparin may increase the hyperkalemic activities of Spironolactone.
Reviparin sodium
Reviparin may increase the hyperkalemic activities of Spironolactone.
Rifaximin
The serum concentration of Rifaximin can be increased when it is combined with Spironolactone.
Rilmenidine
Spironolactone may decrease the vasoconstricting activities of Rilmenidine.
Riociguat
The risk or severity of adverse effects can be increased when Spironolactone is combined with Riociguat.
Risperidone
Spironolactone may increase the hypotensive activities of Risperidone.
Ritodrine
Spironolactone may decrease the vasoconstricting activities of Ritodrine.
Rofecoxib
Rofecoxib may decrease the antihypertensive activities of Spironolactone.
Ropinirole
The risk or severity of adverse effects can be increased when Ropinirole is combined with Spironolactone.
Ropivacaine
The risk or severity of adverse effects can be increased when Ropivacaine is combined with Spironolactone.
Rotigotine
The risk or severity of adverse effects can be increased when Rotigotine is combined with Spironolactone.
Sacubitril
The risk or severity of adverse effects can be increased when Sacubitril is combined with Spironolactone.
Salicylamide
Salicylamide may decrease the antihypertensive activities of Spironolactone.
Salicylic Acid
Salicylic acid may decrease the antihypertensive activities of Spironolactone.
Salmeterol
Spironolactone may decrease the vasoconstricting activities of Salmeterol.
Salsalate
Salsalate may decrease the antihypertensive activities of Spironolactone.
Saralasin
Saralasin may increase the hyperkalemic activities of Spironolactone.
Secobarbital
Secobarbital may increase the hypotensive activities of Spironolactone.
Selegiline
The risk or severity of adverse effects can be increased when Selegiline is combined with Spironolactone.
Serratiopeptidase
Serrapeptase may decrease the antihypertensive activities of Spironolactone.
Sevoflurane
The risk or severity of adverse effects can be increased when Sevoflurane is combined with Spironolactone.
Silodosin
The serum concentration of Silodosin can be increased when it is combined with Spironolactone.
Sodium Phosphate
Spironolactone may increase the nephrotoxic activities of Sodium phosphate.
Sodium Phosphate, Monobasic
Spironolactone may increase the nephrotoxic activities of Sodium phosphate.
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS
Spironolactone may increase the nephrotoxic activities of Sodium phosphate.
Sotalol
The risk or severity of adverse effects can be increased when Spironolactone is combined with Sotalol.
Spirapril
Spironolactone may increase the hyperkalemic activities of Spirapril.
Streptokinase
The risk or severity of adverse effects can be increased when Streptokinase is combined with Spironolactone.
Sufentanil
The risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone.
Sulfasalazine
Sulfasalazine may decrease the antihypertensive activities of Spironolactone.
Sulindac
Sulindac may decrease the antihypertensive activities of Spironolactone.
Suprofen
Suprofen may decrease the antihypertensive activities of Spironolactone.
Synephrine
Spironolactone may decrease the vasoconstricting activities of Synephrine.
Tacrolimus
The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus.
Tamsulosin
The risk or severity of adverse effects can be increased when Tamsulosin is combined with Spironolactone.
Tapentadol
The risk or severity of adverse effects can be increased when Tapentadol is combined with Spironolactone.
Telmisartan
The risk or severity of adverse effects can be increased when Spironolactone is combined with Telmisartan.
Tenoxicam
Tenoxicam may decrease the antihypertensive activities of Spironolactone.
Terazosin
The risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin.
Terbutaline
Spironolactone may decrease the vasoconstricting activities of Terbutaline.
Terbutaline Sulfate
Spironolactone may decrease the vasoconstricting activities of Terbutaline.
Teriflunomide
Teriflunomide may decrease the antihypertensive activities of Spironolactone.
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Spironolactone.
Thiamylal
Thiamylal may increase the hypotensive activities of Spironolactone.
Thiopental
Thiopental may increase the hypotensive activities of Spironolactone.
Thiopental Sodium
Thiopental may increase the hypotensive activities of Spironolactone.
Thioridazine
The risk or severity of adverse effects can be increased when Thioridazine is combined with Spironolactone.
Tiaprofenic Acid
Tiaprofenic acid may decrease the antihypertensive activities of Spironolactone.
Timolol
The risk or severity of adverse effects can be increased when Timolol is combined with Spironolactone.
Timolol Anhydrous
The risk or severity of adverse effects can be increased when Timolol is combined with Spironolactone.
Tinzaparin
Tinzaparin may increase the hyperkalemic activities of Spironolactone.
Tinzaparin sodium
Tinzaparin may increase the hyperkalemic activities of Spironolactone.
Tizanidine
Spironolactone may decrease the vasoconstricting activities of Tizanidine.
Tolazoline
The risk or severity of adverse effects can be increased when Tolazoline is combined with Spironolactone.
Tolcapone
The risk or severity of adverse effects can be increased when Tolcapone is combined with Spironolactone.
Tolfenamic Acid
Tolfenamic Acid may decrease the antihypertensive activities of Spironolactone.
Tolmetin
Tolmetin may decrease the antihypertensive activities of Spironolactone.
Tolvaptan
Tolvaptan may increase the hyperkalemic activities of Spironolactone.
Topotecan
The serum concentration of Topotecan can be increased when it is combined with Spironolactone.
Torsemide
The risk or severity of adverse effects can be increased when Torasemide is combined with Spironolactone.
Tramadol
The risk or severity of adverse effects can be increased when Tramadol is combined with Spironolactone.
Trandolapril
The risk or severity of adverse effects can be increased when Spironolactone is combined with Trandolapril.
Tranilast
Tranilast may decrease the antihypertensive activities of Spironolactone.
Tranylcypromine
The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Spironolactone.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Spironolactone.
Triamterene
Triamterene may increase the hyperkalemic activities of Spironolactone.
Trimethoprim
Trimethoprim may increase the hyperkalemic activities of Spironolactone.
Tulobuterol
Spironolactone may decrease the vasoconstricting activities of Tulobuterol.
Valdecoxib
Valdecoxib may decrease the antihypertensive activities of Spironolactone.
Valsartan
The risk or severity of adverse effects can be increased when Valsartan is combined with Spironolactone.
Verapamil
The risk or severity of adverse effects can be increased when Spironolactone is combined with Verapamil.
Vincristine
The excretion of Vincristine can be decreased when combined with Spironolactone.
Xamoterol
Spironolactone may decrease the vasoconstricting activities of Xamoterol.
Zileuton
Zileuton may decrease the antihypertensive activities of Spironolactone.
Zofenopril
Spironolactone may increase the hyperkalemic activities of Zofenopril.
Zomepirac
Zomepirac may decrease the antihypertensive activities of Spironolactone.
